We use necessary system cookies for the correct functioning of the website and optional Google Analytics cookies to obtain visit statistics.

Cookies config

  • Necessary

    The necessary cookies are absolutely essential for the website to work properly. This category only includes cookies that guarantee basic website security and functionality. These cookies do not store any personal information.

    _GRECAPTCHAgoogle.comOwnprovide antispam protection with the reCaptcha service6 months
    cc_cookie_acceptfidmag.orgOwnUsada per confirmar que l'usuari ha confirmat / refusat les cookies (i quins tipus accepta)1 any
    WEB_SESSIONfidmag.orgOwnCookie técnica: cookie de sessió PHP. Guarda l'id de sessió d' acabar la sessió

  • Analisys

    Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information on meters, the name of visitors, the percentage of bounces, the font of the traffic, etc.

    _gaGoogle AnalyticsFrom third partiesCookie d'anàlisi o mesurament: Identifica els usuaris i proporciona informació sobre com els usuaris troben la pàgina web i com la utilitzen per a realització d'Informes estadístics2 anys
    _gat_gtag_UA_141706552_1Google AnalyticsFrom third partiesCookie d'anàlisi o mesurament: Tracking per part de google per google analytics1 minut
    _gidGoogle AnalyticsFrom third partiesCookie d'anàlisi o mesurament: S'usa per limitar el percentatge de sol·licituds24 hores

ConfigureReject allAccept


Dissecting the clinical and biological heterogeneity of first-episode psychosis: a longitudinal study in a representative cohort


Psychotic disorders are characterised by the presence of delusions, hallucinations, thought disturbance, or neurocognitive deficits. Approximately, 2-3% of the general population is affected by a psychotic disorder across the lifespan, with a widespread impact on the person's individual, social and family life. Early diagnosis and treatment of psychotic disorders are main priorities for the WHO and for the "Mental Health Strategy" of the Spanish Ministry of Health.

The CIBERSAM cohort of individuals with First Episode Psychosis (FEP) and controls, formed between 2016 and 2018 and funded by the IISCIII , served as an anchor point to link and harmonise pre-existing FEP cohorts within CIBERSAM groups, with the ultimate goal of establishing a rich longitudinal cohort with deep phenotyping of all individuals at least at baseline and at a 5-year, 10-year or 15-year follow-up.

In the 2020 AES call, a multicenter project was presented with: 1.- to transform the CIBERSAM cohort into a national cohort of individuals with FEP (i.e. “FEP cohort”, or CoPEP); 2.- to increase the numbers of cases and controls in CoPEP cohort, and 3.- to identify more homogeneous subpopulations within FEP based on cross-sectional assessment of clinical, cognitive and neurobiological variables and their longitudinal trajectories over the first few years of illness in the CoPEP cohort.

The objective of this proposal is to join the Multicenter project led by Dr. David Fraguas (PI20/00216), which is progressing favorably and has demonstrated its viability, providing a sample of controls and patients, as well as scientific collaboration in the exploitation of the results, specifically in the area of neuroimaging.


50.820,00 €

Financing entity

Instituto de Salud Carlos III, con la cofinanciación de Fondo Europeo de Desarrollo Regional "Una manera de hacer Europa"


Logo MICINN Banner ISCIII Logo UE 2022
We are part of
HH Província España
Contact us

Avda. Jordà, 8, 08035 Barcelona
Contact phone: 935 480 105
Online contact 



Reconocimientos a la calidad y la excelencia
Última modificación: 12/07/2024